This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I71 (aortic aneurysm and dissection) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), thoracoabdominal aortic aneurysm, aortic dissection, Stanford type A/B dissection, DeBakey classification types I/II/III |
| C. Adult onset | AAA is most common in male smokers aged 65–80. Acute aortic dissection occurs mainly in hypertensive patients in their 60s–70s, but in connective tissue diseases such as Marfan syndrome it also occurs before age 40. |
| 1. History | 1950s: Gross's first surgical repair of AAA. 1954: DeBakey and Cooley's aneurysm resection and graft replacement. 1991: the first EVAR revolutionized treatment. |
| 2. Causes | Atherosclerosis, hypertension, smoking (AAA), connective tissue diseases (Marfan, Ehlers-Danlos, Loeys-Dietz syndromes) and degeneration of the aortic media are the main causes. |
| 3. Genetics | Variants in genes such as FBN1 (Marfan), TGFBR1/2 (Loeys-Dietz), COL3A1 (Ehlers-Danlos type IV), MYH11 and ACTA2 are associated with heritable aortic disease. |
| 4. General epidemiology | AAA prevalence about 4–8% in men aged 65 and over; aortic dissection incidence 3–6 per 100,000 per year. Mortality of untreated ruptured AAA over 80%. |
| 5. Pathophysiology | Aneurysm: degradation of medial elastic fibers (MMP activation) → weakening of the vessel wall → dilatation. Dissection: intimal tear → false lumen formation → progression or rupture. |
| 6. Symptoms | AAA: mostly asymptomatic, severe abdominal and back pain on rupture. Dissection (type A): sudden tearing chest pain, radiating pain, altered consciousness. Type B: chest and back pain. |
| 7. Signs | AAA: pulsatile abdominal mass. Dissection (type A): pulse deficit, aortic regurgitation, pericardial effusion. A double lumen on CT is characteristic. |
| 8. Screening | Male smokers aged 65 and over: one-time abdominal ultrasound screening. Patients with connective tissue disease (Marfan, Loeys-Dietz): monitoring of aortic diameter with regular MRA/CTA. |
| 9. Diagnosis | Abdominal ultrasound (AAA screening), CTA (evaluation of the whole aorta, confirmation of dissection), MRA (follow-up without radiation exposure), transesophageal echocardiography (emergency dissection). |
| 10. Treatment | AAA: EVAR or open surgery at ≥5.5cm (men) or ≥5.0cm (women) or with rapid growth. Type A dissection: emergency surgery. Type B: blood pressure control, endovascular stent graft. |
| 11. Prognosis | 30-day mortality of elective AAA surgery: EVAR about 1–2%, open surgery about 3–5%. Overall mortality of ruptured AAA about 80%. 48-hour mortality of untreated type A dissection 50%. |
| 12. Prevention | Smoking cessation (most effective for preventing AAA), blood pressure control (beta-blockers, ARBs), regular imaging follow-up in patients with connective tissue disease, and statin therapy contribute to slowing aortic growth. |
| 13. References | ESVS 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms … and 9 other papers |
Aortic aneurysm and dissection appear in medical records from ancient times. The Greek physician Galen first described aneurysms in the 2nd century, and medieval physicians also described pulsatile arterial swellings. However, in the era before surgical treatment, aortic aneurysms almost invariably led to fatal rupture.
The history of modern surgical treatment begins in the mid-20th century. In 1951 Charles Dubost (France) performed the first successful resection of an abdominal aortic aneurysm with homograft replacement. In 1954 Michael DeBakey and Denton Cooley (USA) established aneurysm repair using synthetic vascular grafts (Dacron graft), and for decades thereafter open surgery was the standard treatment for aortic aneurysm. DeBakey also established a classification system for aortic dissection (Type I, II, III) in 1955, which is still used clinically today.
The second revolution in treatment began in 1991, when Juan Parodi (Argentina) first succeeded in percutaneous repair of an abdominal aortic aneurysm using an endovascular stent graft (EVAR, Endovascular Aneurysm Repair). EVAR spread rapidly because it is less invasive than open surgery and allows faster recovery. In the 2000s, endovascular techniques applicable to complex anatomy, such as thoracic EVAR (TEVAR) and branch vessel–preserving EVAR (fenestrated/branched EVAR), were developed. The 2024 ESVS (European Society for Vascular Surgery) guidelines compiled up-to-date, evidence-based guidance on the management of aortic aneurysm.
The causes of aortic aneurysm and dissection differ by shape and location. Abdominal aortic aneurysm (AAA) arises mainly from degenerative (atherosclerotic) causes. Progressive degeneration and degradation of the elastic fibers (elastin) and collagen of the abdominal aortic media weaken the vessel wall. Smoking is the strongest single risk factor for AAA; smokers have about 5 times the risk of AAA of nonsmokers, and the risk increases in proportion to the duration and amount of smoking. Hypertension places a continuous pressure load on the vessel wall, and older age and male sex are independent risk factors. A family history of AAA increases the risk about 2–4-fold.
In thoracic aortic aneurysm and aortic dissection, heritable connective tissue diseases are an important cause. Marfan syndrome (FBN1 gene variants) is a major cause of ascending aortic aneurysm and dissection, as abnormal fibrillin-1 weakens the medial elastic fibers. Bicuspid aortic valve (BAV) is a congenital anomaly that raises the risk of aortic aneurysm along with increased hemodynamic stress on the ascending aortic wall. Hypertension is the most common causative risk factor for dissection (present in about 70–90%). Aortic dissection tends to occur in situations in which blood pressure rises abruptly (strenuous exercise, cocaine use, trauma).
The role of gene variants in heritable aortic disease is very important. Marfan syndrome is caused by autosomal dominant variants in the FBN1 (fibrillin-1) gene, and abnormal fibrillin-1 weakens the elastic structure of the media. In Marfan syndrome, the risk of ascending aortic aneurysm and dissection is dozens of times higher than in people without Marfan syndrome. Loeys-Dietz syndrome is caused by variants in the TGFBR1/2 (TGF-β receptor) or SMAD2/3, TGFB2/3 genes and is characterized by more aggressive aortic lesions than Marfan syndrome.
Vascular Ehlers-Danlos syndrome (vascular EDS, vEDS) is caused by variants in COL3A1 (the type III collagen gene) and carries a very high risk of spontaneous rupture of the aorta and branch vessels. Variants in the ACTA2 (α-smooth muscle actin) and MYH11 (smooth muscle myosin heavy chain) genes cause smooth muscle cell dysfunction and are associated mainly with thoracic aortic disease. In aortic disease associated with BAV (bicuspid aortic valve), variants in NOTCH1, KCNJ2, FBN1 and others have been identified. When heritable aortic disease is suspected, genetic testing with a next-generation sequencing–based aortic disease gene panel, together with family screening, is essential.
The prevalence of abdominal aortic aneurysm (AAA) is about 4–8% in men aged 65 and over and about 1–2% in women. It is higher in male smokers, rising to about 10–15% in male smokers aged 65 and over. About 200,000 AAAs are diagnosed each year in the United States, and about 10,000–15,000 people die annually from AAA rupture. The annual growth rate of AAA differs with mean diameter: about 1–2mm/year below 4cm and about 3–4mm/year at 5–6cm.
The incidence of acute aortic dissection is about 3–6 per 100,000 per year. Stanford type A dissection (involving the ascending aorta) accounts for about 60–70%, and type B (not involving the ascending aorta) for 30–40%. Type A dissection is a cardiac emergency with a 48-hour mortality of about 50% without immediate surgery. Uncomplicated type B dissection can be managed with blood pressure control alone, but endovascular treatment is needed if end-organ ischemia (mesenteric, renal, lower limb) develops. In Korea, the number of operations for aortic disease is steadily increasing along with the growing elderly population.
Degenerative change in the aortic media is central to the pathophysiology of abdominal aortic aneurysm. Fragmentation of elastic fibers and unbalanced degradation of collagen and elastic fibers make the vessel wall fragile. Overactivation of matrix metalloproteinases (MMPs, especially MMP-2 and MMP-9) is important in this process, with MMPs secreted by macrophages and neutrophils degrading elastic fibers. Local inflammatory responses, hypoxia from intra-aortic thrombus formation and atherosclerosis also contribute to medial degeneration.
Aortic dissection begins with an intimal tear of the aorta. When an intimal tear occurs, blood enters the media and separates it into an inner layer (true lumen) and an outer layer (false lumen). As the dissection propagates proximally or distally, it blocks or distorts branch vessels (coronary, carotid, vertebral, celiac, renal, mesenteric and iliac arteries), causing ischemia of the corresponding organs. When the dissection extends to the aortic adventitia, rupture occurs, which is immediately fatal. When retrograde dissection reaches the aortic root, coronary ostial obstruction, aortic regurgitation and pericardial effusion develop.
Most AAAs are asymptomatic and are often found incidentally on abdominal ultrasound or CT. In symptomatic AAA, periumbilical or lumbar pain may occur, and symptoms intensify when rupture is imminent. In ruptured AAA, severe, sudden abdominal and back pain and hemodynamic shock (hypotension, tachycardia, altered consciousness) form the characteristic triad. Rupture often occurs into the retroperitoneal space, so blood pressure may be temporarily maintained, but this is a very unstable state.
The typical symptom of acute aortic dissection is sudden, severe tearing or ripping chest or back pain. Anterior chest pain is characteristic of Stanford type A dissection, and posterior chest and back pain of type B. The pain may migrate from the chest toward the abdomen and lower limbs as the dissection propagates. With coronary involvement in type A dissection, the chest pain resembles that of myocardial infarction, and stroke (neurological symptoms), syncope and heart failure symptoms may accompany it. With mesenteric or renal artery involvement, abdominal pain, hematuria and oliguria develop.
The most characteristic physical examination finding of AAA is palpation of a pulsatile abdominal mass. A pulsatile, expansile mass felt in the mid-abdomen strongly suggests AAA. However, palpation may be difficult in obese patients, and sensitivity is about 60–70%. In ruptured AAA, abdominal tenderness, flank tenderness, abdominal rigidity and hypotension are observed.
A characteristic finding of type A aortic dissection is a pulse deficit: a blood pressure difference between the two arms (≥20mmHg) or loss of the carotid or femoral pulse on one side only. An aortic regurgitation murmur is heard when retrograde dissection reaches the aortic root. If cardiac tamponade from pericardial effusion develops—elevated jugular venous pressure, hypotension and muffled heart sounds—immediate treatment is needed. Spinal cord ischemia causes lower limb paralysis, and renal artery involvement causes elevated blood pressure and oliguria.
The evidence-based method of AAA screening is a one-time abdominal ultrasound in high-risk groups. The US Preventive Services Task Force (USPSTF) and most international guidelines recommend one-time screening abdominal ultrasound in male smokers aged 65–75 (10 or more pack-years). In Korea, too, abdominal ultrasound in health checkups is used for screening. With a family history (a first-degree relative with AAA), it is recommended to begin screening in men aged 55 and over.
In heritable thoracic aortic disease (Marfan syndrome, Loeys-Dietz, BAV, etc.), the baseline aortic diameter is measured by chest and abdominal MRA or CTA immediately after diagnosis, followed by regular imaging follow-up at 6–12-month intervals depending on aortic size. In Marfan syndrome, the baseline diameter and growth rate of the aortic root are the key indicators for deciding the timing of preventive surgery.
Abdominal ultrasound is the most practical method for AAA screening and size follow-up (sensitivity 96%, specificity 99%). However, CT angiography (CTA) is the standard for preoperative planning or evaluation of dissection. CTA precisely evaluates the overall anatomy of the aorta, its size, relationships with branch vessels, thrombus and signs of leakage, and is essential for surgical planning.
In diagnosing acute aortic dissection, CTA shows excellent sensitivity (96–100%) and specificity (96–100%) for identifying the intimal flap and double lumen. In hemodynamically unstable patients, transesophageal echocardiography (TEE) is useful for rapidly confirming dissection. MRA can evaluate aortic morphology without radiation exposure and is preferred in young patients requiring repeated follow-up, such as those with Marfan syndrome. Blood tests include D-dimer (elevated in dissection), creatinine (renal ischemia) and troponin (to differentiate myocardial ischemia).
Treatment decisions for AAA are based on size, growth rate and the patient's surgical risk. In the 2024 ESVS guidelines, the indications for elective surgery are a maximum diameter ≥5.5cm (men) or ≥5.0cm (women), or a growth rate ≥1cm per year. The surgical method is chosen between endovascular stent graft repair (EVAR) and open surgical repair (OSR), taking into account the patient's anatomical conditions (landing zone, branch vessel anatomy) and life expectancy. EVAR has lower 30-day mortality than OSR, but a higher long-term reintervention rate, and endoleak is a problem. For AAAs below the minor surgical indication (4.5–5.5cm), ultrasound follow-up at 6–12-month intervals is carried out together with blood pressure control, smoking cessation and statin therapy.
For acute Stanford type A aortic dissection, immediate surgery is the only lifesaving option. Surgery replaces the ascending aorta and, when needed, repairs the aortic arch, aortic valve and coronary arteries. In uncomplicated Stanford type B dissection, blood pressure control (systolic blood pressure target 100–120mmHg, IV beta-blockers or labetalol) and heart rate control come first. In complicated or progressive type B dissection, a thoracic endovascular stent graft (TEVAR) covers the intimal tear to block blood flow into the false lumen.
The 30-day mortality of elective AAA surgery is about 1–2% for EVAR and about 3–5% for open surgery. However, for ruptured AAA, overall mortality including prehospital deaths reaches about 80–90%, which is extremely poor. In-hospital operative mortality for ruptured AAA is also high, at about 40–50%. This underscores the importance of early screening and preventive surgery. The 5-year survival rate after EVAR is about 65%, and similar after open surgery. About 15–20% of EVAR patients require reintervention for complications such as endoleak.
The 30-day mortality after surgery for acute type A aortic dissection is about 15–25%. Because the mortality within 48 hours without treatment reaches 50%, the benefit of immediate surgical treatment is clear. Even in survivors the risk of aortic dilatation and redissection persists, so lifelong regular imaging follow-up and blood pressure control are needed. The 5-year survival rate of patients with type B dissection is about 60–80%, and adherence to blood pressure control and smoking cessation is decisive for the long-term prognosis.
In AAA prevention, smoking cessation is the single most important preventive measure. Not smoking markedly reduces the risk of AAA, and in patients who already have a small AAA, smoking cessation slows the rate of aortic growth. Blood pressure control (beta-blockers, RAAS inhibitors, calcium channel blockers) reduces aortic wall stress and contributes to slowing AAA growth. In patients with Marfan syndrome, beta-blockers (including losartan) have been shown in randomized studies to reduce the rate of aortic root dilatation. Evidence for a direct effect of statins on slowing AAA growth is limited, but they are recommended to reduce overall cardiovascular risk.
In heritable aortic disease (Marfan, Loeys-Dietz, bicuspid aortic valve), family screening detects asymptomatic carriers early and regular imaging follow-up is started. Patients with Marfan syndrome are educated to avoid contact sports, extreme isometric exercise (heavy weightlifting) and highly competitive sports, and to minimize situations in which blood pressure spikes. Drugs that cause extreme blood pressure elevation (cocaine, stimulants) are strong triggers of aortic dissection, so their use is absolutely prohibited.
Wanhainen A, Van Herzeele I, Bastos Gonçalves F, et al. Editor's Choice — European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024;67(2):192-331. DOI: 10.1016/j.ejvs.2023.11.002. PMID: 38307694.
Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873-2926. DOI: 10.1093/eurheartj/ehu281. PMID: 25173340.
Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022;146(24):e334-e482. DOI: 10.1161/CIR.0000000000001106. PMID: 36322642.
Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Ann Vasc Surg. 1991;5(6):491-499. DOI: 10.1007/BF02015271. PMID: 1837729.
Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000;283(7):897-903. DOI: 10.1001/jama.283.7.897. PMID: 10685714.
Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994;330(19):1335-1341. DOI: 10.1056/NEJM199405123301902. PMID: 8152445.
Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476-485. DOI: 10.1136/jmg.2009.072785. PMID: 20591885.
Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Ann Intern Med. 1997;126(6):441-449. DOI: 10.7326/0003-4819-126-6-199703150-00004. PMID: 9072929.
Siebert U, Alagoz O, Bayoumi AM, et al. Screening for abdominal aortic aneurysm in men 65 to 75 years who have ever smoked: an evidence-based systematic review. Ann Intern Med. 2007;146(8):580-590. DOI: 10.7326/0003-4819-146-8-200704170-00008. PMID: 17438316.
De Bruin JL, Baas AF, Buth J, et al. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med. 2010;362(20):1881-1889. DOI: 10.1056/NEJMoa0907217. PMID: 20484396.